Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 8/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661955 | 0.90 | PARP1 (0.48) | PARP1SORT1LCKPTGESPHGDH | |
| SCHEMBL12661874 | 0.90 | PARP1 (0.48) | PARP1SORT1LCKDHODH | |
| SCHEMBL12661921 | 0.90 | PARP1 (0.48) | PARP1SORT1LCKPTGESDHODH | |
| SCHEMBL12662089 | 0.85 | PARP1 (0.60) | PARP1HDAC3HDAC7HDAC10HDAC6 | |
| SCHEMBL12673103 | 0.83 | PARP1 (0.62) | PARP1SORT1LCKPHGDHDHODH | |
| SCHEMBL12662305 | 0.83 | PHGDH (0.43) | PARP1PTGESPHGDH | |
| SCHEMBL1896561 | 0.82 | PARP1 (0.65) | PARP1HDAC3HDAC7HDAC10HDAC6 | |
| SCHEMBL12661868 | 0.82 | PARP1 (0.59) | PARP1HDAC3HDAC7HDAC10HDAC6 | |
| SCHEMBL12662052 | 0.81 | PARP1 (0.62) | PARP1HDAC3HDAC7HDAC10HDAC6 | |
| SCHEMBL13551074 | 0.79 | PARP1 (0.66) | PARP1HDAC3HDAC7HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PARP1 287/4885HDAC3 13/4885HDAC7 32/4885 |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PARP1 331/4885HDAC3 11/4885HDAC7 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.